04 June 2019
Article by Clarivate published with permission.
Clarivate Analytics, a global leader in providing trusted insights and analytics to accelerate the pace of innovation, has signed an agreement to provide drug discovery intelligence across the Melbourne Biomedical Precinct (MBP).
Under the agreement, The University of Melbourne, Monash University, BioCurate and The Walter Eliza Hall Institute of Medical Research will have enterprise-wide access to Cortellis drug discovery intelligence to support their strategic research practices from early science through drug discovery. Cortellis is a suite of life science solutions from Clarivate Analytics that inform decision-making across the drug/device development and commercialization spectrum.
Through Cortellis, MBP precinct members will be able to use key scientific information and insights to prioritize drug development candidates, benchmark other companies, and assess the competitive landscape early in the research process. The data is available via a single point of access to Cortellis, enabling a fast, efficient and comprehensive view of an indication and its potential.
“We are pleased to deliver rich scientific intelligence to MBP in one easily searchable platform,” said Mukhtar Ahmed, President of Life Sciences at Clarivate Analytics.
“By using Cortellis, Australian researchers will have access to a wealth of scientific pipeline data that includes granular target and mechanism of action (MOA) information as well as extensive preclinical and clinical biomarker data linked to associated diseases and therapies.”
Scientific data included in Cortellis spans more than 500,000 drugs and biologics, 6,600 targets, 41,000 biomarkers, 2.9 million biomarker uses, 2.4 million pharmacology data points, 99,000 experimental models and 430,000 patents. The solution was developed by scientists for scientists, and features intelligence that has been manually curated and validated by Clarivate’s content operations teams.
“By using Cortellis data, our researchers will be able to rapidly assess drug targets and biomarkers, molecules in development and treatment pathways to assess both their translational and fundamental research impact,” said Andy Allen, PhD, Senior Academic Fellow, School of Biomedical Sciences, The University of Melbourne.
“Having a single source of integrated biological, chemical and pharmacological data will greatly advance our efforts to drive innovation and support better decision-making early in the drug development process.”
The Melbourne Biomedical Precinct is Australia’s leading biomedical precinct. It is made up of over 40 hospitals, research, teaching and biotechnology organizations in Melbourne, the second largest city in Australia.